Long-read sequencing: match the technology to the unresolved mechanism
Longer molecules can clarify structural variation and difficult regions, but analytical validation and study design still determine diagnostic value.
The reading room
Explore medical genetics
Find a starting point, a clinical perspective, or a closer look at the research.
13 articles
Single-cell genomics: more cells do not replace more participants
Cell atlases reveal biological heterogeneity, but meaningful disease comparisons require sound sampling, batch handling and independent replication.
DNA methylation episignatures: biomarkers with a defined scope
A reproducible methylation pattern can support a diagnosis, but classifier coverage and validation determine how much it can resolve.
Functional variant assays: abnormal biology is not automatically pathogenicity
Assay validation, disease mechanism and clinical calibration determine whether a laboratory observation can strengthen variant classification.
CRISPR screens: from a selected hit to a defensible mechanism
A screen identifies candidates under particular experimental conditions; orthogonal evidence is needed before treating a hit as a disease mechanism or therapeutic target.
Population reference datasets: rarity, constraint and ancestry in context
Reference databases are essential for variant interpretation, but absence, group labels and gene-level constraint each require careful qualification.
ClinVar discordance: investigate the assertions behind the summary
Conflicting classifications are a prompt to inspect evidence, scope and dates rather than count votes.
Gene–disease validity: establish the association before classifying a candidate
A plausible variant cannot compensate for an uncertain relationship between the gene and the proposed disorder.
From GWAS signal to mechanism: why the nearest gene is not the answer
Association identifies a genomic neighborhood; causal variants, target genes and biological effects require additional evidence.
Rare-disease data sharing: make data useful without treating access as unlimited
FAIR principles and responsible governance can support discovery while preserving consent, privacy and accountability.
Gene therapy evidence: distinguish early response from durable benefit
A one-time administration still requires long-term evidence about effectiveness, late adverse events and who remains represented in follow-up.
Rare-disease trial endpoints: measure a change that matters
Small populations make endpoint selection more demanding, not less; connect measurement quality, natural history and patient relevance.